EPREX Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
March 24, 2017
March 24, 2017
BEERSE, Belgium, March 24 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, issued the following news release:
Janssen-Cilag International NV today announced the French health authority Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), has approved EPREX(R) (epoetin alfa) for the treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic sy . . .
Janssen-Cilag International NV today announced the French health authority Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), has approved EPREX(R) (epoetin alfa) for the treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic sy . . .